期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Effect of trimebutine in combined with alprazolam on the gastrointestinal hormones in patients with diarrhea-type IBS 被引量:1
1
作者 Yong-Li Yang Chun-Qiu Song +2 位作者 Hong-Xia Li Xiao-Feng Huang Hong-Mei Zhou 《Journal of Hainan Medical University》 2017年第19期47-50,共4页
Objective: To explore the effect of trimebutine in combined with alprazolam on the gastrointestinal hormones and living quality in patients with diarrhea-type IBS (IBS-D). Methods: A total of 117 patients with IBS-D w... Objective: To explore the effect of trimebutine in combined with alprazolam on the gastrointestinal hormones and living quality in patients with diarrhea-type IBS (IBS-D). Methods: A total of 117 patients with IBS-D who were admitted in our hospital were included in the study and randomized into the control group (n=58) and the treatment group (n=59). The patients in the control group were given trimebutine;while the patients in the treatment group were given trimebutine in combined with alprazolam. The patients in the two groups were continuously treated for 4 weeks. The levels of gastrointestinal hormones and brain-gut peptide before and after treatment in the two groups were detected and compared. SF-36 was used to analyze the living quality before and after treatment in the two groups. Results: MOT;GAS;SP;and 5-HT levels after treatment in the two groups were significantly reduced;while VIP;SS;CCK;and CGRP levels and SF-36 score in each dimension were significantly elevated;and the comparison between the two groups was statistically significant. Conclusions:Trimebutine in combined with alprazolam in the treatment of IBS-D can significantly improve the gastrointestinal hormones and brain-gut peptide;and enhance the living quality;with a significant efficacy. 展开更多
关键词 trimebutine ALPRAZOLAM IBS-D GASTROINTESTINAL HORMONE Living quality
下载PDF
Therapeutic Analysis of Fuzi Lizhong Wan with Trimebutine in the Treatment of Diarrhea Type lrritable Bowel Syndrome
2
作者 Ying Chang Quanwei Di Gaixian Di 《Journal of Clinical and Nursing Research》 2020年第4期40-44,共5页
Objective:To evaluate the clinical efficacy ofFuzi Lizhong Wan and trimebutine in the treatment of diarrhea irritab1e bowel syndrome.Methods:A tota1 of 90 patients with diarrhea irritable Dow1 syndrome were divided in... Objective:To evaluate the clinical efficacy ofFuzi Lizhong Wan and trimebutine in the treatment of diarrhea irritab1e bowel syndrome.Methods:A tota1 of 90 patients with diarrhea irritable Dow1 syndrome were divided intocontro1 group(n=45)and treatment group(n=45)using the random.number table method.Patients in the control group were po administered withtrimebutine 0.2 g.three time daily for 4 weeks.Patients in the treatment group were po administered with Fuzi Lizhong Wan 9 g,three time daily for 4 weeks on the basis of the control group.The clinical efficacy and the TCM symptom scores were evaluated after treatment.The serological indicators in two groups were compared before and after treatment.Results:After treatment,the clinica1 efficacy and the TCM symptom scores in treatment group were significantly 1ower than that in contro1 group(P<0.05).The 1evels of serological indicators in both groups improved significant1y,and those in the treatment group were better than the control group(P<0.05).Conclusion:Combined therapy of Fuzi Lizhong Wan and trimebutine in the treatment of diarrhea type irritable bowe1 syndrome has a significant effect,which canrelieve clinical symptom;and reduce visceral sensitivity,and improve leve1s of inflammatory and quality of life.So it is suggested to be applied. 展开更多
关键词 Fuzi Lizhong Wan trimebutine Diarrhea irritable bowel syndrome
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部